Glenmark Pharmaceuticals has entered into an agreement with J.B. Chemicals & Pharmaceuticals to divest its cardiac brand, Razel (Rousvastatin and combinations), in India and Nepal for a consideration amount of Rs 313.7 crore. Razel and its combinations are indicated for the management of dyslipidemia. The transaction is expected to be closed by the end of this calendar year, subject to customary closing formalities.
This divestment is in line with Glenmark’s strategy of focusing on other sub?categories of the cardio?vascular segment. Going forward, the company will continue to further consolidate its position in its core therapeutic areas of cardio?metabolic, respiratory, dermatology, and oncology.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
